Aqemia is an in silico drug discovery start-up, whose ambition is to discover rapidly more innovative therapeutic molecules with better chances of success. How? Just like an AI can learn to play chess, Aqemia’s generative AI learns to invent relevant compounds thanks to unique Statistical Mechanics algorithms predicting drug-target affinity among other properties. Aqemia’s differentiation lies in its affinity prediction both accurate and 10 000x faster than competition, enabling efficient guidance of generation towards compounds with better chances to become drugs.
Aqemia is a spin-off of the École Normale Supérieure Paris leveraging disruptive algorithms from 8 years of research. Aqemia’s team is composed of a dozen of high profiles at the crossroads of Medicinal Chemistry, Statistical Mechanics and Artificial Intelligence. Founded in June 2019, we have raised €1.6M with leading VC fund Elaia Partners, Bpifrance and business angels. Our office is located in the center of Paris at Agoranov, a top-notch deeptech incubator.